Literature DB >> 6833432

Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation.

R R Brown, R Bain, V C Jordan.   

Abstract

Sensitive and reproducible analyses were developed for assaying tamoxifen, monohydroxytamoxifen, N-desmethyltamoxifen, metabolite E [trans-1(4-hydroxyphenyl)1,2-diphenylbut-1-ene] and a new metabolite, metabolite Y [trans-1(4-hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene] in human serum using high-performance liquid chromatography (HPLC). Three different systems were developed for specific purposes. All chromatography was performed using serum extracts made with hexane-butanol. Detection was by fluorimetry of phenanthrene derivatives formed by on-stream UV irradiation with a newly described device for post-column irradiation of the HPLC stream. This device may be of use in other HPLC systems requiring post-column photochemical reactions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833432     DOI: 10.1016/s0378-4347(00)86138-1

Source DB:  PubMed          Journal:  J Chromatogr


  16 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts.

Authors:  Nilesh W Gaikwad; William J Bodell
Journal:  Free Radic Biol Med       Date:  2011-10-18       Impact factor: 7.376

3.  Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues.

Authors:  G K Poon; G M Bisset; P Mistry
Journal:  J Am Soc Mass Spectrom       Date:  1993-07       Impact factor: 3.109

4.  Proceedings of the British Pharmacological Society. Liverpool, 6th-8th April, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

5.  Inability of tamoxifen to penetrate into cerebrospinal fluid.

Authors:  S Noguchi; K Miyauchi; S Imaoka; H Koyama
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

6.  Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.

Authors:  Alan H B Wu; Wendy Lorizio; Simone Tchu; Kara Lynch; Roy Gerona; Wuyang Ji; Weiming Ruan; Kathryn J Ruddy; Stephen D Desantis; Harold J Burstein; Elad Ziv
Journal:  Breast Cancer Res Treat       Date:  2012-06       Impact factor: 4.872

7.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 8.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 9.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

10.  Short term high density systemic therapy for metastatic breast cancer.

Authors:  D C Tormey; J C Kline; M Palta; T E Davis; R R Love; P P Carbone
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.